ADMA Biologics Cash Flow Statement
NASDAQ: ADMAHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
ADMA Biologics free cash flow
In fiscal 2025, ADMA Biologics generated $50.4 million of operating cash flow and spent $22.6 million on capital expenditures. That left free cash flow of $27.8 million, a free-cash-flow margin of 5.5% of revenue. Free cash flow was down 74.8% from the prior year's $110.4 million.
ADMA Biologics returned $31.9 million to shareholders through share repurchases, equal to 115% of free cash flow.
Summary generated from market data by MetaCap's automated system. Methodology
ADMA Biologics cash flow statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | 146.93M | 197.67M | -28.24M | -65.90M | -71.65M | -75.75M | -48.28M | -65.74M | -43.76M | -19.52M |
| Net Income growth (YoY) | -25.67% | — | — | — | — | — | — | — | — | — |
| Depreciation & Amortization | 8.00M | 7.70M | 7.60M | 6.40M | 4.80M | 3.20M | 2.40M | 2.60M | 1.50M | 400.00K |
| Stock-Based Compensation | 20.03M | 13.62M | 6.19M | 5.21M | 3.49M | 2.86M | 2.65M | 2.22M | 1.56M | 1.25M |
| Change in Working Capital | -145.09M | -19.60M | -18.73M | -25.94M | -58.25M | -36.28M | 39.70M | -3.55M | 44.55K | -774.13K |
| Operating Cash Flow | 50.40M | 118.67M | 8.80M | -59.51M | -112.37M | -102.00M | -76.19M | -62.68M | -37.27M | -18.27M |
| Capital Expenditures | -22.57M | -8.23M | -4.77M | -13.91M | -13.51M | -12.73M | -3.81M | -2.10M | -2.68M | -73.41K |
| Investing Cash Flow | -21.89M | -8.57M | -4.98M | -13.91M | -13.51M | -12.72M | -3.81M | -2.10M | 15.21M | 904.58K |
| Share Repurchases | -31.94M | 0 | 0 | — | — | — | — | — | — | — |
| Debt Issued | — | — | — | — | — | 27.50M | 72.50M | 0 | 30.00M | 4.00M |
| Debt Repaid | — | — | — | — | — | -13.95M | -30.00M | — | — | — |
| Financing Cash Flow | -44.02M | -58.30M | -38.99M | 108.85M | 121.05M | 143.90M | 80.00M | 42.92M | 60.75M | 16.84M |
| Net Change in Cash | -15.52M | 51.80M | -35.17M | 35.43M | -4.83M | 29.17M | -2.72K | -21.85M | 38.69M | -526.09K |
| Free Cash Flow | 27.82M | 110.45M | 4.03M | -73.42M | -125.88M | -114.73M | -80.01M | -64.77M | -39.95M | -18.34M |
This table shows 10 annual periods of ADMA Biologics's cash flow statement, from FY 2025 back to FY 2016, across 13 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow ADMA's reporting calendar. What is a cash flow statement?